case 3: fgfr-targeted therapy adverse events in bladder cancer
Published 4 years ago • 66 plays • Length 5:24Download video MP4
Download video MP3
Similar videos
-
7:18
case 3: experience with fgfr-targeted therapies in bladder cancer
-
4:18
case 3: treatment for fgfr3 bladder cancer
-
2:13
case 3: mutational patterns in bladder cancer
-
2:29
additional insights: experience with fgfr inhibitors in bladder cancer
-
4:25
fgfr inhibitor moa and adverse events
-
7:12
case 3: molecular testing in bladder cancer
-
4:11
an overview of targeted fgfr3 therapy in bladder cancer with dr. siefker-radtke
-
1:54
targeted therapy effective for patients with advanced bladder cancer and specific gene mutations
-
5:16
the future of fgfr inhibitor treatment
-
3:02
discussion on trial investigating erdafitinib in patients with urothelial cancer
-
3:50
fgfr-specific tkis versus multikinase inhibitors
-
20:21
targeted therapy for the treatment of advanced metastatic urothelial cancer youtube
-
6:00
fgfr inhibitor toxicity profile
-
13:53
molecular testing and treatment sequencing for advanced uc: navigating fgfr-targeted therapy
-
12:14
the latest in bladder cancer with fgfr 2 and 3 mutations
-
1:29:54
examining the state of the science on new therapies in bladder cancer
-
7:31
fgfr inhibition in advanced cca
-
4:03
fgfr inhibitors for cca & bladder cancer
-
4:24
case 4: multiple lines of therapy in recurrent bladder cancer